Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1723 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-07-31

Study Completion Date

2008-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Post-Marketing Surveillance study evaluating the Efficacy, Tolerability and Safety of Olmesartan medoxomil 20 mg in combination with 12.5 MG of hydrochlorothiazide in subjects with mild to moderate essential hypertension

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension

NCT00139698

Essential Hypertension

COMPLETED PHASE3

Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension

NCT00890591

Essential Hypertension

COMPLETED PHASE4

Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

NCT00430950

Essential Hypertension

COMPLETED PHASE3

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension

NCT00412932

Hypertension

COMPLETED PHASE4

Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker

NCT00185120

Hypertension

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Non Probability Sampling

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Olmesartan medoxomil + HCTZ

Olmesartan medoxomil

Intervention Type DRUG

olmesartan medoxomil 20 mg and HCTZ 12.5 mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Olmesartan medoxomil

olmesartan medoxomil 20 mg and HCTZ 12.5 mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and Female patients 18 to 65 y/old
* Patient previously taking low-dose medoxomil or any other ARB alone with uncontrolled BP
* Patient with uncontrolled mild to moderate hypertension (SBP\>= 140 and \<=179 mmHg OR DBP of \>=90 and \<=109 mmHg)